Community curated by people like you

Congenital Adrenal Hyperplasia stories

Oct 15, 2026

OMass Therapeutics raises $310M for genetic adrenal disorder treatment

UK biotech OMass Therapeutics collected $310 million in one of the largest private financings for a British biotech in recent years, seeking to develop treatments for congenital adrenal hyperplasia and compete with Neurocrine and Vertex.

Oct 15, 2026·3 sources

00

Top claims

▪OMass Therapeutics announced on October 15, 2026 that it closed a $310 million Series C financing round to advance its rare endocrine disorder pipeline
▪Vertex Pharmaceuticals acquired the clinical drug candidate atumelnant through its $10 billion acquisition of Crinetics Pharmaceuticals
▪Standard treatment for congenital adrenal hyperplasia relies on high doses of synthetic glucocorticoids, which cause severe side effects and risk life-threatening adrenal crisis if cortisol levels drop

Related timelines

AI Data Center Gold Rush

Congress

Congress

Crypto hacks

Iran War